

Superoxide generation and leukocyte accumulation: key elements in the mediation of leukotriene B₄-induced itch by transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1

Elizabeth S. Fernandes,* Chi Teng Vong,^{†,‡,1} Samuel Quek,^{†,‡,1} Jessica Cheong,^{†,‡,1} Salma Awal,^{†,‡} Clive Gentry,[§] Aisah A. Aubdool,^{†,‡} Lihuan Liang,^{†,‡} Jennifer V. Bodkin,^{†,‡} Stuart Bevan,[§] Richard Heads,^{†,‡} and Susan D. Brain^{†,‡,2}

*Programa de Pós-Graduação em Biologia Parasitária, Universidade Ceuma, São Luís, Brazil; and [†]Cardiovascular Division and [‡]Centre for Integrative Biomedicine, British Heart Foundation King's College London Cardiovascular Centre of Excellence, and [§]Wolfson Centre for Age Related Disease, King's College London, London, UK

ABSTRACT The underlying mechanisms of itch are poorly understood. We have investigated a model involving the chemoattractant leukotriene B₄ (LTB₄) that is up-regulated in common skin diseases. Intradermal injection of LTB₄ (0.1 nmol/site) into female CD1 mice induced significant scratching movements (used as an itch index) compared with vehicle-injected (0.1% bovine serum albumin-saline) mice. Intraperitoneal transient receptor potential (TRP) channel antagonist treatment significantly inhibited itch as follows: TRP vanilloid 1 (TRPV1) antagonist SB366791 (0.5 mg/kg, by 97%) and the TRP ankyrin 1 (TRPA1) antagonists TCS 5861528 (10 mg/kg; 82%) and HC-030031 (100 mg/kg; 76%). Leukotriene B₄ receptor 2 antagonism by LY255283 (5 mg/kg i.p.; 62%) reduced itch. Neither TRPV1-knockout (TRPV1-KO) nor TRPA1-knockout (TRPA1-KO) mice exhibited LTB₄-induced itch compared with their wild-type counterparts. The reactive oxygen species scavengers *N*-acetylcysteine (NAC; 204 mg/kg i.p.; 86%) or superoxide dismutase (SOD; 10 mg/kg i.p.; 83%) also inhibited itch. LTB₄-induced superoxide release was attenuated by TCS 5861528 (56%) and HC-030031 (66%), NAC (58%), SOD (50%), and LY255283 (59%) but not by the leukotriene B₄ receptor 1 antagonist U-75302 (9 nmol/site) or SB366791. Itch, superoxide, and

myeloperoxidase generation were inhibited by the leukocyte migration inhibitor fucoidan (10 mg/kg i.v.) by 80, 61, and 34%, respectively. Myeloperoxidase activity was also reduced by SB366791 (35%) and SOD (28%). TRPV1-KO mice showed impaired myeloperoxidase release, whereas TRPA1-KO mice exhibited diminished production of superoxide. This result provides novel evidence that TRPA1 and TRPV1 contribute to itch *via* distinct mechanisms.—Fernandes, E. S., Vong, C. T., Quek, S., Cheong, J., Awal, S., Gentry, C., Aubdool, A. A., Liang, L., Bodkin, J.V., Bevan, S., Heads, R., Brain, S.D. Superoxide generation and leukocyte accumulation: key elements in the mediation of leukotriene B₄-induced itch by transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1. *FASEB J.* 27, 000–000 (2013). www.fasebj.org

Key Words: pruritus • inflammation • neutrophils • reactive oxygen species • skin

ITCH IS AN UNPLEASANT sensation experienced at least once in a lifetime that causes the desire to scratch. It is a common symptom of many systemic and dermatological diseases, and it is also triggered by several physiological and psychogenic factors. Itch involves complex mechanisms and requires a fine interaction between cutaneous and neuronal effectors. Although scratching produces temporary relief of itch, this response rarely remedies the chronic condition (for review, see ref. 1).

Abbreviations: BLT1, leukotriene B₄ receptor 1; BLT2, leukotriene B₄ receptor 2; BSA, bovine serum albumin; CGRP, calcitonin gene-related peptide; DMSO, dimethyl sulfoxide; G-CSFR, granulocyte colony-stimulating factor receptor; LTB₄, leukotriene B₄; MPO, myeloperoxidase; NAC, *N*-acetylcysteine; NK₁, neurokinin receptor 1; NOX, NADPH oxidase; O₂⁻, superoxide; PCR, polymerase chain reaction; PLA₂, phospholipase A₂; ROS, reactive oxygen species; SOD, superoxide dismutase; SP, substance P; TRP, transient receptor potential; TRPA1, transient receptor potential ankyrin 1; TRPV1, transient receptor potential vanilloid 1; TRPA1-KO, transient receptor potential ankyrin 1-knockout; TRPV1-KO, transient receptor potential vanilloid 1-knockout; UVB, ultraviolet B; WT, wild type

¹ These authors contributed equally to this work.

² Correspondence: King's College London, Franklin-Wilkins Bldg., Waterloo Campus, 150 Stamford St., London SE1 9NH, UK. E-mail: sue.brain@kcl.ac.uk

doi: 10.1096/fj.12-221218

It is well known that itch and pain share common neurophysiological pathways, and the threshold of sensing itch and pain and the mechanisms underlying these responses are of debate.

Sensory nerves are suggested to mediate the acute transmission and sensitization of itch. In fact, an important role for the neuronal expressed neuropeptides substance P (SP) and calcitonin gene-related peptide (CGRP) as well for the transient receptor potential (TRP) vanilloid 1 (TRPV1) in itch has been documented (for review, see ref. 1), whereas the non-neuronal expression of TRPV1 channels in mediating this response can only be speculated on. Evidence suggests that TRPV1 can be found in different cells and tissues that form the skin, such as epidermal keratinocytes, dermal blood vessels, and mast cells (2, 3). Notably, topical application of the TRPV1 agonist capsaicin (0.05% capsaicin cream), which causes depletion of the neurogenic component on repeated application, is being used to treat severe itch (for review, see ref. 4). Although the role of TRPV1 in itch has been studied, very little is known of the participation of other TRP channels in itch. Recently, a novel histamine-independent role for TRP ankyrin 1 (TRPA1) as a downstream activator in itch was suggested (5). TRPA1 can be found in ~50% of the sensory nerves coexpressing TRPV1 (6), and, similarly to TRPV1, TRPA1 neuronal activation is linked to the release of SP and CGRP (7–9), and expression of TRPA1 can be also found in non-neuronal skin cells and tissues, such as keratinocytes, fibroblasts, and melanocytes (10, 11). TRPV1 and TRPA1 are differently activated by exogenous and endogenous agonists. It is important to highlight here that, besides their colocalization in sensory neurons, these channels present other similarities, such as their activation by a nonselective agonist, such as hydrogen peroxide (H₂O₂; refs. 12, 13).

We investigated the role of TRPV1 and TRPA1 in mediating leukotriene B₄ (LTB₄)-induced itch. LTB₄ is a potent chemoattractant for leukocytes released from the leukocytes themselves, in addition to mast cells and keratinocytes (14–16) and it is known to cause and mediate itch in rodents (17–20). Indeed, increased levels of LTB₄ have been associated with patients with a range of itch-associated diseases such as atopic dermatitis (21), Sjögren-Larsson syndrome (22), and psoriasis (23). Recently, LTB₄-induced itch has been shown to be involved in two distinct murine models of chronic atopic dermatitis (24) and chronic dermatitis (25). However, it is not clear how LTB₄ mediates itch.

Here, we investigated the mechanisms associated with the pruriceptive itch induced by LTB₄. We found that after LTB₄ injection, there is increased TRPV1 and TRPA1 expression in the skin. By analyzing different steps of the inflammation caused by LTB₄ in the skin, our data reveal distinct pathways *via* which TRPV1 and TRPA1 contribute to itch.

MATERIALS AND METHODS

Animals

Female CD1 mice (20–25 g; Charles River, Margate, Kent, UK) were used. In addition, female mice (25–35 g), either genetically unaltered [wild-type (WT)] or TRPV1-knockout (TRPV1-KO; C57BL/6×129SvJ background; ref. 26), and WT and TRPA1-knockout (TRPA1-KO; C57BL/6J background; ref. 27), were used. Mice were kept in a climatically controlled environment with *ad libitum* access to food and water and were acclimatized in the procedure room for 1 h before the experiments. All experiments were performed in accordance with the UK Home Office Animals (Scientific Procedures) Act of 1986 and local King's College London ethics approval. All recovery procedures were performed under isoflurane anesthesia (2% isoflurane-2% O₂).

LTB₄-induced scratching

The protocol is similar to that described previously by Costa *et al.* (28). At 24 h before the experiments, the hair at the back of the mouse neck was shaved. On the day of the experiments, the animals were placed individually in a clear acrylic cage with a floor area of 170 cm² for ≥1 h to acclimatize them. Then, each mouse was briefly removed from the chamber and given an intradermal injection of LTB₄ (0.1 nmol/site, 50 μl; Tocris Biosciences, Abingdon, UK; ref. 17) or vehicle [0.1% bovine serum albumin (BSA) in saline, 50 μl; Sigma-Aldrich, Poole, UK]. Immediately after treatment, the animals were put back into the same cages and observed for 40 min. Scratching behavior was quantified by counting the number of scratches with forepaws and hindpaws close to the injected site and used as an index of itch. Results are expressed as the number of total scratches in 40 min. Ear grooming was recorded over 40 min and used as an index of emotional (stress-related) changes associated with LTB₄ injection.

Pharmacological treatments

The participation of LTB₄ receptors was evaluated by using leukotriene B₄ receptor 1 (BLT1) and leukotriene B₄ receptor 2 (BLT2) antagonists, U-75302 (9 nmol/site, dissolved in saline after ethanol evaporation; ref. 29) and LY255283 [5 mg/kg *i.p.*, 30 min; dissolved in 10% dimethyl sulfoxide (DMSO) in saline; ref. 19], respectively (both from Cayman Chemical, Cambridge, UK). To assess the involvement of mast cell degranulation, mice were pretreated with the mast cell stabilizer disodium cromoglycate (8 mg/kg *i.p.*, 1×/d for 6 d; Sigma-Aldrich; ref. 28). The contribution of TRPV1 activation was analyzed in mice treated with the selective TRPV1 antagonist SB366791 (0.5 mg/kg *i.p.*, dissolved in 1% DMSO saline; Sigma-Aldrich; ref. 30) 30 min before LTB₄ injection. The TRPA1 contribution was investigated in mice pretreated with the selective TRPA1 antagonist HC-030031 (100 mg/kg *i.p.*, dissolved in 10% DMSO in saline; Chembridge Corp., San Diego, CA, USA; ref. 31) or TCS5861528 (10 mg/kg *i.p.*, dissolved in 2% DMSO in saline; Tocris Biosciences; ref. 32) 30 min before LTB₄ treatment. The participation of neuropeptides was evaluated by coinjection of the CGRP receptor antagonist CGRP₈₋₃₇ or the neurokinin receptor 1 (NK₁) antagonist SR140333 (1 nmol/site) with LTB₄ (33, 34). Leukocyte migration was investigated by using the nonspecific selectin inhibitor fucoidan (10 mg/kg *i.v.*, 15 min, dissolved in saline; Sigma-Aldrich; ref. 35) before LTB₄ injection. Reactive oxygen species (ROS) participation was assessed in mice treated either with *N*-acetylcysteine (NAC; 204 mg/kg *i.p.*, dissolved in saline; Sigma-Aldrich; ref. 36) or

standard superoxide dismutase (SOD; 10 mg/kg i.p., dissolved in saline; Sigma-Aldrich; ref. 37) 30 min before LTB₄ treatment. LTB₄ stock solutions were prepared in ethanol and kept at -80°C. Just before the experiments, the ethanol was evaporated, and LTB₄ was resuspended in 0.1% BSA in saline.

Measurement of neutrophil accumulation

Neutrophil recruitment to the dorsal skin was assessed indirectly by quantification of tissue myeloperoxidase (MPO) activity according to the method described previously (35). In brief, the dorsal skin samples treated with either vehicle or LTB₄ (0.1 nmol/site) were collected 40 min after the injections; homogenized in buffer containing 600 mM NaCl, 600 mM KH₂PO₄, 66 mM Na₂HPO₄, and 0.5% hexadecyl-trimethyl-ammonium bromide; and centrifuged at 4°C for 20 min at a speed of 12,000 rpm. For enzymatic reaction, 25 µl of the resultant supernatant was then incubated with 25 µl of assay buffer (50 mM phosphate buffer, pH 6, and 0.5% hexadecyl-trimethyl-ammonium bromide) and 100 µl of KBlue (Neogen Corp., Ayr, Scotland), a stabilized preparation of H₂O₂ and tetramethylbenzidine, for 15 min at 37°C. Absorbance was measured at 620 nm, and results were normalized to protein content. Protein content in each sample was measured at 562 nm, by using a BCA protein assay kit (Thermo Scientific, Cramlington, UK). MPO activity is expressed as optical density per milligram of protein.

Measurement of H₂O₂

H₂O₂ levels in dorsal skin samples were measured using the Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit (Invitrogen, Paisley, UK) as described previously by Keeble *et al.* (37), with minor modifications. In brief, dorsal skin samples were collected 40 min after LTB₄ injection and homogenized in a phosphate buffer (0.05 M NaPO₄, pH 7.4; 1 ml/sample) containing sodium azide (0.01 M). The homogenates were centrifuged at 4°C for 10 min at 10,000 rpm, and the supernatants were filtered through Millipore tubes (0.5 µm diameter) by centrifugation at 4°C for 2 min at 10,000 rpm. Then 100 µl of sample was incubated with 100 µl of a solution containing 0.05 M NaPO₄ (pH 7.4), horseradish peroxidase (0.2 U/ml), and Amplex Red reagent (10-acetyl-3,7-dihydroxyphenoxazine; 25.7 µg/ml) for 2 h at 37°C. Absorbance was read at 560 nm, and the readings obtained for samples incubated in the absence or presence of Amplex Red reagent were compared to a H₂O₂ standard curve (0-40 µM). Results are expressed as the difference between samples incubated in the presence or absence of Amplex Red (micromolar). H₂O₂ levels and were normalized to protein content. H₂O₂ levels are expressed as micromoles per liter per milligram of protein.

Superoxide (O₂⁻) measurements

O₂⁻ release from fresh dorsal skin samples was measured by chemiluminescence using lucigenin (bis-*N*-methylacridinium nitrate; Sigma-Aldrich) as a probe (38). Chemiluminescence was measured using a GloMax 20/20 luminometer (Promega, Southampton, UK). In brief, dorsal skin samples were collected 40 min after LTB₄ injection. Modified Krebs' buffer (100 µl, pH 7.4, composition of 131 mM NaCl, 5.6 mM KCl, 25 mM NaHCO₃, 1 mM NaH₂PO₄ · H₂O, 5 mM glucose, 5 mM HEPES, 100 µM L-arginine, 2.5 mM CaCl₂, 1 mM MgCl₂, and 100 µM NADPH) was added to each Eppendorf tube containing individual skin samples. Then 100 µl of Krebs' buffer containing lucigenin (10 mM) and NADPH (500 µM;

Sigma-Aldrich) was added to the samples in the presence or absence of SOD (50 U/ml). Chemiluminescence was recorded after 4 min. Results are expressed as the difference in the relative light units per milligram of protein in the presence and absence of SOD after subtraction of background luminescence.

Gene expression analysis

Quantitative mRNA expression in skin samples was determined by real-time polymerase chain reaction (PCR). In brief, dorsal skin samples were collected 40 min after LTB₄ injection and stored in RNAlater until RNA extraction was performed. DNA-free total RNA was extracted from the samples using the RNeasy Microarray Kit (Qiagen, Crawley, UK), and 0.5 µg of total RNA was reverse transcribed to cDNA using the high capacity RNA-to-cDNA kit with RNase inhibitor (Applied Biosystems, Paisley, UK) according to the manufacturer's instructions. Real-time PCR (hold for 10 min at 95°C; cycling for 45 cycles: 10 s at 95°C, 15 s at 57°C, and 5 s at 72°C; and melt at 68-90°C) was performed on a Corbett Rotor-Gene (Qiagen) using the SensiMix SYBR No-ROX Kit (Bioline, London, UK). The following primers were obtained from Sigma-Aldrich: TRPA1 forward 5'-AGGTGATTTTTAAAA-CATTGCTGAG-3' and reverse 5'-CTCGATAATTGATGTC-TCTAGCAT-3'; TRPV1 forward 5'-CAACAAGAAGGGGCT-TACACC-3' and reverse 5'-TCTGGAGAATGTAGGCCAA-GAC-3'; granulocyte colony-stimulating factor receptor (G-CSFR) forward 5'-TATGCTAGGGTCCAGCGAGT-3' and reverse GGGAGGCTCCAATTTTACA-3'; actin forward 5'-CACAGCTTCTTTGCAGCTCCTT-3' and reverse 5'-TCAG-TATACCTCTCTTGCTCT-3'; phospholipase A₂ (PLA₂) forward 5'-TGGATATAAACCATCTCCACCA-3' and reverse 5'-GGGAAGGGATACCTATGTTTCAGA-3'; and β₂-microglobulin forward 5'-CCTGCAGAGTTAAGCATGCC-3' and reverse 5'-GATGCTTGATCACATGTCTCG-3'.

Results are expressed as copy number per microliter of pure cDNA normalized by comparison with actin, β₂-microglobulin, and PLA₂ using geNorm 3.4 (<http://medgen.ugent.be/~jvdesomp/genorm/>). All experiments were performed in accordance with minimum information for publication of quantitative real-time PCR experiments guidelines.

Statistical analysis

Results are presented as the means ± SE of 6-11 animals. The percentage of inhibition is reported as the mean ± SE for each individual experiment. Statistical comparison was performed by analysis of variance followed by the Bonferroni test or by use of Student's unpaired *t* test. Values of *P* < 0.05 were considered significant.

RESULTS

LTB₄-induced itch is mediated by BLT2

LTB₄ intradermal injection to the dorsal neck skin caused a robust scratching (2.9-fold increase), expressed as number of scratches over 40 min (Fig. 1A), compared with that for control (vehicle)-treated animals. The majority of scratches were performed with the mouse hindpaws rather than with forepaws, and scratching peaked between 0 and 20 min after LTB₄ injection (Fig. 1A). Ear-grooming activity was not different between control and LTB₄-treated mice, suggest-




Figure 1. LTB₄-induced itch is dependent on BLT2 activation. *A*) LTB₄-induced scratching behavior in CD1 mice. Itch was induced by an interdermal injection of LTB₄ (0.1 nmol/site, 50 μ l). Vehicle-treated (0.1% BSA in saline, 50 μ l) animals were used as controls. Scratching behavior was quantified by counting the number of scratches with forepaws and hindpaws close to the injected site, and it was taken as an index of itch. *B*) Ear grooming was quantified over 40 min. *C, D*) Effect of the pretreatment with the BLT2 antagonist LY255283 (5 mg/kg i.p., 30 min; *C*) and BLT1 antagonist U-75302 (9 nmol/site; coinjected with LTB₄; *D*) on LTB₄-induced scratching behavior. Results are expressed as the number of scratches or ear grooming in 40 min. * $P < 0.05$ vs. control group; $n = 5-6$ /group.

ing that LTB₄ injection into the back of the neck evokes minor stress-related changes in mice (Fig. 1*B*). This response was reduced by the selective BLT2 antagonist LY255283 (61.5 \pm 9.2% inhibition) but not by the BLT1 antagonist U-75302 (Fig. 1*C, D*, respectively). Mast cell products are known to play a role in itching. To determine the role of mast cell products in LTB₄-induced itch, mice received a repeated treatment with the mast cell stabilizer cromoglycate (8 mg/kg i.p., 6-d treatment). Cromoglycate did not affect LTB₄-induced itch (control, 33.3 \pm 9.9 scratches; LTB₄, 123.8 \pm 17.9 scratches; and LTB₄ + cromoglycate, 117.6 \pm 14.9 scratches), suggesting no involvement of mast cells in this model.

TRPV1 and TRPA1 are important mediators of LTB₄-induced itch

LTB₄-induced itch was abolished by pretreatment with either the selective TRPV1 antagonist SB366791 (97.1 \pm 2% inhibition; Fig. 2*A*) and not observed in TRPV1-KO mice (Fig. 2*B*). The selective TRPA1 antagonists TCS 5861528 (81.7 \pm 7.4% inhibition) and HC-030031 (76.1 \pm 15.8% inhibition) also induced a highly significant inhibition of itch (Fig. 2*C*). Moreover, LTB₄ was not able to elicit a scratching behavior in TRPA1-KO

mice (Fig. 2*D*). Notably, expression of both TRPV1 and TRPA1 mRNA was increased in dorsal skin samples after LTB₄ injection, although this increase was only significant for the TRPV1 gene (Fig. 2*E, F*). These results indicate the direct involvement of TRPV1 and TRPA1 in LTB₄-induced itch. Release of CGRP and SP is a common event triggered by TRPV1/TRPA1 activation. However, our data suggest that there is no participation of local release of these neuropeptides in the itch response after LTB₄ injection because coinjection of either the selective CGRP receptor antagonist CGRP₈₋₃₇ or the NK₁ antagonist, SR140333 with LTB₄ did not affect scratching behavior (Fig. 2*G*).

Role for leukocyte migration and O₂⁻ release in LTB₄-induced itch

LTB₄ is a potent chemoattractant for polymorphonuclear leukocytes (39). We investigated whether leukocyte migration plays a role in LTB₄-induced itch. As shown in Fig. 3*A*, there was a marked reduction (79.8 \pm 8.4%) in itch after pretreatment with a leukocyte migration blocker, the nonspecific selectin inhibitor fucoidan. MPO was increased (1.6-fold increase) in LTB₄-treated dorsal skin biopsy samples 40 min after injection compared with that in control (vehicle) sam-




Figure 2. Contribution of TRPV1 and TRPA1 activation and neuropeptide release to LTB₄-induced itch. *A, C, D*) Effect of the pretreatment with the selective TRPV1 antagonist SB366791 (0.5 mg/kg i.p., 30 min; *A*) or the TRPA1 antagonists TCS 5861528 (10 mg/kg i.p., 30 min; *C*) or HC-030031 (100 mg/kg i.p., 30 min; *D*) on LTB₄-induced scratching behavior. *B, D*) LTB₄-induced itch in TRPV1 (*B*) and TRPA1 (*D*) WT and TRPA1-KO mice. *E, F*) TRPV1 (*E*) and TRPA1 (*F*) mRNA expression as copy numbers per milliliter of pure cDNA normalized by comparison with actin, β_2 -microglobulin, and PLA₂. *G*) Effect of the coinjection with LTB₄ of either the CGRP antagonist CGRP₈₋₃₇ or the NK₁ antagonist SR140333 (1 nmol/site) on LTB₄-induced scratching behavior. Vehicle-treated animals were used as controls. Itch experiment results are expressed as the number of scratches in 40 min. **P* < 0.05 vs. control group; #*P* < 0.05 vs. LTB₄-treated animals; *n* = 6-8/group for itch experiments; *n* = 6/group for mRNA quantification.

the number of scratches in 40 min. **P* < 0.05 vs. control group; #*P* < 0.05 vs. LTB₄-treated animals; *n* = 6-8/group for itch experiments; *n* = 6/group for mRNA quantification.

ples (Fig. 3*B*), and this response was decreased to basal levels with fucoidan (33.6 ± 6.5% inhibition; Fig. 3*B*). Moreover, mRNA analysis of LTB₄-treated dorsal skin biopsy samples revealed increased expression of G-CSFR, which was predominantly expressed on neutrophils (40) compared with expression in vehicle-treated samples (Fig. 3*C*).

Results depicted in Fig. 4*A* show that although blockade of BLT1 by U-75302 does not affect MPO release caused by LTB₄ treatment with the selective BLT2 antagonist LY255283 caused a 1.8-fold increase of neutrophil accumulation in the skin. Notably, intraperitoneal pretreatment with the TRPV1 antagonist SB366791 but not the TRPA1 antag-

onist HC-030031 blocked the MPO increase induced by LTB₄ intradermal injection (34.7 ± 7.3% inhibition; Fig. 4*B*). TRPV1-KO mice also showed a deficient but not total inhibition of neutrophil accumulation in LTB₄-treated skin biopsy samples compared with its vehicle control and LTB₄-injected WT (Fig. 4*C*). In addition, intraperitoneal pretreatment with the O₂⁻ scavenger SOD significantly reduced MPO levels in LTB₄-treated skin samples (27.8 ± 8.7% inhibition; Fig. 4*D*).

Activated leukocytes are known to release ROS (41). Therefore, we examined whether ROS production is involved in LTB₄-induced scratching behavior. Sys-




Figure 3. Role of leukocyte influx on LTB₄-induced itch. *A-C*) Effect of the pretreatment with the nonspecific selectin inhibitor fucoidan (10 mg/kg i.v., 15 min) on scratching behavior (*A*), leukocyte influx (*B*), and G-CSFR mRNA expression levels (*C*) in the skin after LTB₄ injection. Vehicle-treated animals were used as controls. Results are expressed as the number of scratches in 40 min (*A*), leukocyte influx (MPO, percentage to control normalized to protein content; *B*), or copy numbers per milliliter of pure cDNA normalized by comparison with actin, β_2 -microglobulin, and PLA₂ (*C*). **P* < 0.05 vs. control group; #*P* < 0.05 vs. LTB₄-treated animals; *n* = 6-8/group for itch experiments; *n* = 6/group for mRNA quantification.




Figure 4. TRPV1 but not TRPA1, in addition to O_2^- generation, mediates leukocyte influx induced by LTB₄. **A, B, D)** Effect of pretreatment with the BLT2 antagonist LY255283 (5 mg/kg i.p., 30 min; **A**) or the BLT1 antagonist U-75302 (9 nmol/site, coinjected with LTB₄; **A**), the TRPA1 antagonist HC-030031 (100 mg/kg i.p., 30 min; **B**), or the TRPV1 antagonist SB366791 (0.5 mg/kg i.p., 30 min; **B**) and SOD (10 mg/kg i.p., 30 min; **D**) on LTB₄-induced MPO. **C)** LTB₄-induced MPO skin levels in TRPV1 WT and TRPV1-KO mice. Dorsal skin samples were collected 40 min after LTB₄ injection. Vehicle-treated animals were used as controls. Results are expressed as MPO (percentage to control normalized to protein content). * $P < 0.05$ vs. control group; # $P < 0.05$ vs. LTB₄-treated animals; $n = 6-8$ /group.

temic pretreatment with the antioxidant NAC or the O_2^- scavenger SOD was shown to significantly decrease LTB₄-induced itch (**Fig. 5A, B**), with inhibition of 85.9 ± 12.1 and $83.1 \pm 7.2\%$, respectively. LTB₄ injection had no effect on H₂O₂ (**Fig. 5C**) but caused release of O_2^- (1.9-fold increase; **Fig. 5E**) over a similar 40-min period after its injection in the dorsal skin compared with that in control samples. *In vitro* addition of SOD into the lucigenin assay reduced O_2^- release from skin samples (**Fig. 5D**). O_2^- release was diminished ($58.7 \pm 17.2\%$) by BLT2 but not BLT1 antagonism (**Fig. 5E**). There was also a marked reduction in O_2^- production ($61.1 \pm 7.3\%$) in skin samples obtained from fucoidan-pretreated mice (**Fig. 5F**). Moreover, O_2^- release was abolished in animals pretreated with NAC or SOD (57.7 ± 8.3 and $49.5 \pm 10.4\%$ inhibition, respectively; **Fig. 5G**). Notably, O_2^- production induced by LTB₄ was significantly reduced by the TRPA1 antagonists HC-030031 and TCS 5861528 given intraperitoneally before LTB₄ injection (65.9 ± 6.1 and $55.9 \pm 5.8\%$ inhibition, respectively; **Fig. 5H**). Similarly, TRPA1-KO mice failed to produce O_2^- after LTB₄ injection (**Fig. 5I**). On the other hand, pretreatment with the TRPV1 antagonist SB366791 did not affect O_2^- levels (**Fig. 5H**).

DISCUSSION

Prurceptive itch occurs in the skin as a result of inflammation, dryness, or other skin damage (for review, see ref. 4). Herein, we used a model of prurceptive itch induced by a single intradermal injection of LTB₄, known to be up-regulated in skin conditions associated with atopic dermatitis, Sjögren-Larsson syndrome, and psoriasis (21–24). We found that LTB₄ injection causes itch *via* an intricate network of cells, inflammatory mediators, and receptors and involves pathways both dependent on and independent of LTB₄ receptor activation. We present evidence that LTB₄ causes mRNA up-regulation of both TRPV1 and TRPA1,

which, as we show here, are important players in the itch triggered by this mediator. LTB₄-induced itch requires polymorphonuclear cell accumulation, which is dependent on TRPV1 activation and O_2^- production by skin-resident cells but independent of BLT. These leukocytes contribute to further O_2^- generation, which involves TRPA1 and BLT2 activation. Thus, we show for the first time distinct roles for TRPV1 and TRPA1 in mediating itch in an inflammatory model relevant to a number of skin diseases. Moreover, we report on a new prurceptive pathway involving TRP channels, polymorphonuclear leukocyte accumulation, and O_2^- generation.

A role for LTB₄ in itch was originally suggested from studies in mice by Andoh and Kuraishi (17). As mentioned previously, LTB₄ can be released by a range of cells (14–16), and its effects are mediated by G-protein-coupled receptors named BLT1 and BLT2, expressed in a variety of cells (42, 43). The recent discovery that TRPV1 and TRPA1 can be sensitized/activated after activation of G-protein-coupled receptors involved in itch *via* protein kinase C/phospholipase C phosphorylation (5, 44) led us to investigate the participation of TRPV1/TRPA1 activation and show how it affects ROS generation and neutrophil migration caused by LTB₄, thus contributing to itch.

We show that LTB₄ triggers itch *via* its BLT2 and that the selective TRPV1 and TRPA1 antagonists, as well as inhibitors of O_2^- production and cell migration, all produced similar reduction of the itch elicited by LTB₄, highlighting the complex nature of prurceptive itch. We provide evidence that LTB₄ promotes oxidative stress *via* O_2^- release after activation of BLT2. Recently, a link between ROS generation and BLT2 activation has been suggested (45, 46). Ultraviolet B (UVB) exposure triggers LTB₄ release from keratinocytes, thus activating BLT2 expressed on keratinocytes, which in turn leads to the release of ROS and subsequent apoptosis (45). A similar cascade was observed in




Figure 5. H₂O₂ and O₂⁻ release induced by LTB₄ in the mouse dorsal skin. *A, B*) Effect of the antioxidant NAC (204 mg/kg i.p., 30 min; *A*) or SOD (10 mg/kg i.p., 30 min; *B*) on LTB₄-induced scratching behavior. *C, D*) H₂O₂ (*C*) and O₂⁻ (*D*) levels in dorsal skin samples treated intradermally with LTB₄ or vehicle (control). *E–H*) O₂⁻ levels in dorsal skin samples obtained from animals pretreated with the BLT2 receptor antagonist LY255283 (5 mg/kg i.p., 30 min; *E*) or the BLT1 receptor antagonist U-75302 (9 nmol/site; conjoined with LTB₄; *E*); pretreated with fucoidan (10 mg/kg i.v., 15 min; *F*), the antioxidant NAC (204 mg/kg i.p., 30 min; *G*) or SOD (10 mg/kg i.p., 30 min; *G*) or the selective TRPV1 antagonist SB366791 (0.5 mg/kg i.p., 30 min; *H*), the selective TRPA1 antagonists TCS 5861528 (10 mg/kg i.p., 30 min; *H*) and HC-030031 (100 mg/kg i.p., 30 min; *H*) after LTB₄ injection. *I*) LTB₄-induced O₂⁻ skin levels in TRPA1 WT and TRPA1-KO mice. Dorsal skin samples were collected 40 min after LTB₄ injection. Vehicle-treated animals were used as controls. Results are expressed as MPO (percentage to control normalized to protein content). **P* < 0.05 vs. control group; #*P* < 0.05 vs. LTB₄-treated animals; *n* = 6-8/group.

fibroblasts, which were shown to produce O₂⁻ *via* BLT2 activation (47). In addition, LTB₄ was suggested to trigger H₂O₂ release from macrophages (48). On the other hand, this was not observed in our study because both vehicle- and LTB₄-treated skin biopsy samples presented similar levels of this mediator, which may be due to rapid degradation of H₂O₂ by catalase and/or glutathione peroxidase. Indeed, both enzymes are known to play a role in H₂O₂ scavenging in the skin in stressful conditions such as after UVB exposure (49).

LTB₄ is known to induce neutrophil migration *via* BLT1 (50, 51) and that, once activated, these cells produce ROS (52, 53). Notably, we found that neutrophil migration in our model of itch induced by LTB₄ is independent of BLT1 and that blocking of BLT2 causes a further increase in neutrophil accumulation in the

skin. This result, associated with the fact that the TRPV1 antagonist SB-366791 inhibits neutrophil migration, allows us to speculate that there is direct activation of TRPV1 by LTB₄ in our model. These results may indicate a dual mechanism by which LTB₄ modulates neutrophil accumulation in this model; *i.e.*, LTB₄ could limit neutrophil migration when activating BLT2 but promote neutrophil migration when activating TRPV1 in our model. Notably, our results show that O₂⁻ levels are directly linked to the effects of LTB₄ on neutrophil migration, which we describe herein as a first wave of O₂⁻ production in our model. We also found that while stimulating this first wave of O₂⁻ *via* resident cells (potentially keratinocytes and blood vessels), LTB₄ stimulates TRPV1 activation, which is shown here to be another key controlling mechanism of neutrophil migration. There is

evidence that LTB₄-dependent neutrophil accumulation occurs *via* TRPV1 activation (54). This earlier study evaluated TRPV1 participation by using capsazepine, which it is known to affect other receptors in addition to TRPV1 (55). Here we show a similar pathway for neutrophil migration induced by LTB₄ by using the selective TRPV1 antagonist SB366791 and also TRPV1-KO mice. This finding strongly suggests that LTB₄ requires direct activation of TRPV1 to exert its chemotactic actions on neutrophils. We also found increased TRPV1 mRNA expression in LTB₄-treated skin biopsy samples. Indeed, there are suggested links between O₂⁻ production and TRPV1 up-regulation, involving NADPH oxidase (NOX) activation (56).

A second wave of O₂⁻ release, which is dependent on neutrophil migration, is described in our study. As mentioned previously, neutrophils are an important source of O₂⁻ release, which accounts for the ability of these cells to participate in host defense (for review, see ref. 57). O₂⁻ generation in these cells is also driven by NOX2 activation and translocation and phosphorylation of p47phox (58), whereas NOX4 is an important regulator of O₂⁻ production in the vasculature and fibroblasts (59). In addition to TRPV1, TRPA1 mRNA was found to be increased after LTB₄ challenge. Although there were low copy numbers of mRNA of these receptors in the skin biopsy samples, we cannot overrule the potential of a greater TRPA1 expression at protein level. There is a lack of selective antibodies; thus, such experimental evidence is not possible to obtain at present. TRPA1 is known as an “oxidant sensor” and, thus, becomes activated in the presence of H₂O₂ and O₂⁻ (13, 60). TRPA1 is also a sensor of hypochlorite and hypochlorous acid (13), which are generated on myeloperoxidase-mediated oxidation of Cl⁻ anion (61). We highlight the fact that O₂⁻ and products of myeloperoxidase activation, such as hypochlorous acid, can react to form a hydroxyl radical, which further increases oxidative stress (for review, see ref. 62). This pathway may play an important role in our model, considering that skin fibroblasts and keratinocytes stimulated by UVA/UVB light have been demonstrated to produce hydroxyl radicals (49, 63). We found that O₂⁻ release but not neutrophil migration induced by LTB₄ is dependent on TRPA1 activation. In addition, TRPA1 activation exhibits a degree of importance similar to that of BLT2 in O₂⁻ production as noted by the percentage of inhibition of O₂⁻ release caused by both BLT2 antagonism and TRPA1 antagonism or deletion. Overall, we can hypothesize the existence of two pathways leading to TRPA1 activation: TRPA1 activation that is due to neutrophil migration and O₂⁻ production from these cells; and TRPA1 activation that is independent of neutrophil migration but is a result of O₂⁻ production from skin-resident cells such as keratinocytes and blood vessels instead. Either way, our data clearly show, for the first time to our knowledge, that TRPA1 activation contributes to O₂⁻ production.

We have established herein that LTB₄-induced itch is dependent on TRPV1 and TRPA1 activation, acting *via* mechanisms independent of local release of CGRP and

SP. These results strongly suggest that TRPV1 and TRPA1 activation may occur in non-neuronal cells located in the skin. On the other hand, the contribution of central release of these neuropeptides after TRPV1 and TRPA1 activation for further itch sensitization cannot be discounted.

In summary, we show that LTB₄ requires a coordinated interaction between different cell types and receptors in the skin. We suggest a pivotal cascade of events in which TRPV1 and TRPA1 play distinct roles with respect to neutrophil migration and O₂⁻ release, respectively. Taken together, these data contribute to the recognition of potentially important novel mechanisms, which may lead to a better understanding of itch associated with inflammatory conditions such as atopic dermatitis and psoriasis. **[F]**

This work was supported by the Arthritis Research UK (grant 19296 to E.S.F.), Biotechnology and Biological Sciences Research Council (A.A.A.), a Capacity Building Award in Integrative Mammalian Biology funded by the Biotechnology and Biological Sciences Research Council, Higher Education Funding Council for England, Knowledge Transfer Network, Medical Research Council, and Scottish Funding Council (L.L.), and British Heart Foundation 4-Year Ph.D. program (J.V.B.). The authors declare no conflicts of interest.

REFERENCES

- Davidson, S., and Giesler, G. J. (2010) The multiple pathways for itch and their interactions with pain. *Trends Neurosci.* **33**, 550–558
- Ständer, S., Moormann, C., Schumacher, M., Buddenkotte, J., Artuc, M., Shpacovitch, V., Brzoska, T., Lippert, U., Henz, B. M., Luger, T. A., Metz, D., and Steinhoff, M. (2004) Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. *Exp. Dermatol.* **13**, 129–139
- Bíró, T., Tóth, B. I., Marincák, R., Dobrosi, N., Géczy, T., and Paus, R. (2007) TRP channels as novel players in the pathogenesis and therapy of itch. *Biochim. Biophys. Acta* **1772**, 1004–1021
- Metz, M., Grundmann, S., and Ständer, S. (2011) Pruritus: an overview of current concepts. *Vet. Dermatol.* **22**, 121–131
- Wilson, S. R., Gerhold, K. A., Bifolck-Fisher, A., Liu, Q., Patel, K. N., Dong, X., and Bautista, D. M. (2011) TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch. *Nat. Neurosci.* **14**, 595–602
- Anand, U., Otto, W. R., Facer, P., Zebda, N., Selmer, I., Gunthorpe, M. J., Chessell, I. P., Sinisi, M., Birch, R., and Anand, P. (2008) TRPA1 receptor localisation in the human peripheral nervous system and functional studies in cultured human and rat sensory neurons. *Neurosci. Lett.* **438**, 221–227
- Pan, X. Q., Gonzalez, J. A., Chang, S., Chacko, S., Wein, A. J., and Malykhina, A. P. (2010) Experimental colitis triggers the release of substance P and calcitonin gene-related peptide in the urinary bladder via TRPV1 signaling pathways. *Exp. Neurol.* **225**, 262–273
- Engel, M. A., Leffler, A., Niedermirtl, F., Babes, A., Zimmermann, K., Filipović, M. R., Izidorczyk, I., Eberhardt, M., Kichko, T. I., Mueller-Tribbenensee, S. M., Khalil, M., Siklasi, N., Nau, C., Ivanović-Burmazović, I., Neuhuber, W. L., Becker, C., Neurath, M. F., and Reeh, P. W. (2011) TRPA1 and substance P mediate colitis in mice. *Gastroenterology* **141**, 1346–1358
- Engel, M. A., Khalil, M., Mueller-Tribbenensee, S. M., Becker, C., Neuhuber, W. L., Neurath, M. F., and Reeh, P. W. (2011) The proximodistal aggravation of colitis depends on substance P released from TRPV1-expressing sensory neurons. *J. Gastroenterol.* **47**, 256–265

10. Atoyán, R., Shander, D., and Botchkareva, N. V. (2009) Non-neuronal expression of transient receptor potential type A1 (TRPA1) in human skin. *J. Invest. Dermatol.* **129**, 2312–2315
11. Bíró, T., and Kovács, L. (2009) An “ice-cold” TR(i)P to skin biology: the role of TRPA1 in human epidermal keratinocytes. *J. Invest. Dermatol.* **129**, 2096–2099
12. Ruan, T., Lin, Y. S., Lin, K. S., and Kou, Y. R. (2006) Mediator mechanisms involved in TRPV1 and P2X receptor-mediated, ROS-evoked bradykinin reflex in anesthetized rats. *J. Appl. Physiol.* **101**, 644–654
13. Andersson, D. A., Gentry, C., Moss, S., and Bevan, S. (2008) Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. *J. Neurosci.* **28**, 2485–2494
14. Camp, R. D., Woollard, P. M., Mallet, A. I., Fincham, N. J., Ford-Hutchinson, A. W., and Bray, M. A. (1982) Neutrophil aggregating and chemokinetic properties of a 5,12,20-trihydroxy-6,8,10,14-eicosatetraenoic acid isolated from human leukocytes. *Prostaglandins* **23**, 631–641
15. Iwamoto, I., Tomoe, S., Tomioka, H., Yoshida, S. (1993) Leukotriene B₄ mediates substance P-induced granulocyte infiltration into mouse skin. Comparison with antigen-induced granulocyte infiltration. *J. Immunol.* **151**, 2116–2123
16. Zhu, Y., Wang, X. R., Peng, C., Xu, J. G., Liu, Y. X., Wu, L., Zhu, Q. G., Liu, J. Y., Li, F. Q., Pan, Y. H., You, B. M., and Hu, J. H. (2009) Induction of leukotriene B₄ and prostaglandin E₂ release from keratinocytes by protease-activated receptor-2-activating peptide in ICR mice. *Int. Immunopharmacol.* **9**, 1332–1336
17. Andoh, T., and Kuraishi, Y. (1998) Intradermal leukotriene B₄, but not prostaglandin E₂, induces itch-associated responses in mice. *Eur. J. Pharmacol.* **353**, 93–96
18. Andoh, T., Katsube, N., Maruyama, M., and Kuraishi, Y. (2001) Involvement of leukotriene B₄ in substance P-induced itch-associated response in mice. *J. Invest. Dermatol.* **117**, 1621–1626
19. Kim, H. J., Kim, D. K., Kim, H., Koh, J. Y., Kim, K. M., Noh, M. S., Lee, S., Kim, S., Park, S. H., Kim, J. J., Kim, S. Y., and Lee, C. H. (2008) Involvement of the BLT2 receptor in the itch-associated scratching induced by 12-(S)-lipoxygenase products in ICR mice. *Br. J. Pharmacol.* **154**, 1073–1078
20. Tsuji, F., Aono, H., Tsuboi, T., Murakami, T., Enomoto, H., Mizutani, K., and Inagaki, N. (2010) Role of leukotriene B₄ in 5-lipoxygenase metabolite- and allergy-induced itch-associated responses in mice. *Biol. Pharm. Bull.* **33**, 1050–1053
21. Ruzicka, T., Simmet, T., Peskar, B. A., Ring, J. (1986) Skin levels of arachidonic acid-derived inflammatory mediators and histamine in atopic dermatitis and psoriasis. *J. Invest. Dermatol.* **86**, 105–108
22. Willemsen, M. A., Lutt, M. A., Steijlen, P. M., Cruysberg, J. R., van der Graaf, M., Nijhuis-van der Sanden, M. W., Pasman, J. W., Mayatepek, E., and Rotteveel, J. J. (2001) Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome. *Eur. J. Pediatr.* **160**, 711–717
23. Brain, S., Camp, R., Dowd, P., Black, A. K., and Greaves, M. (1984) The release of leukotriene B₄-like material in biologically active amounts from the lesional skin of patients with psoriasis. *J. Invest. Dermatol.* **83**, 70–73
24. Andoh, T., Haza, S., Saito, A., and Kuraishi, Y. (2011) Involvement of leukotriene B₄ in spontaneous itch-related behaviour in NC mice with atopic dermatitis-like skin lesions. *Exp. Dermatol.* **20**, 894–898
25. Tsukumo, Y., Harada, D., and Manabe, H. (2010) Pharmacological characterization of itch-associated response induced by repeated application of oxazolone in mice. *J. Pharmacol. Sci.* **113**, 255–262
26. Fernandes, E. S., Russell, F. A., Spina, D., McDougall, J. J., Graepel, R., Gentry, C., Staniland, A. A., Mountford, D. M., Keeble, J. E., Malcangio, M., Bevan, S., and Brain, S. D. (2011) A distinct role for transient receptor potential ankyrin 1, in addition to transient receptor potential vanilloid 1, in tumor necrosis factor α -induced inflammatory hyperalgesia and Freund's complete adjuvant-induced monoarthritis. *Arthritis Rheum.* **63**, 819–829
27. Andersson, D. A., Gentry, C., Alenmyr, L., Killander, D., Lewis, E., Andersson, A., Bucher, B., Galzi, J. L., Sterner, O., Bevan, S., Högestätt, E. D., and Zygmunt, P. M. (2011) TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid Δ^9 -tetrahydrocannabinol. *Nat. Commun.* **2**, 551
28. Costa, R., Marotta, D. M., Manjavachi, M. N., Fernandes, E. S., Lima-Garcia, J. F., Paszcuk, A. F., Quintão, N. L., Juliano, L., Brain, S. D., and Calixto, J. B. (2008) Evidence for the role of neurogenic inflammation components in trypsin-elicited scratching behaviour in mice. *Br. J. Pharmacol.* **154**, 1094–1103
29. Gomides, L. F., Duarte, I. D., Ferreira, R. G., Perez, A. C., Francischi, J. N., and Klein, A. (2012) Proteinase-activated receptor-4 plays a major role in the recruitment of neutrophils induced by trypsin or carrageenan during pleurisy in mice. *Pharmacology* **89**, 275–28230
30. Eid, S. R., Crown, E. D., Moore, E. L., Liang, H. A., Choong, K. C., Dima, S., Henze, D. A., Kane, S. A., and Urban, M. O. (2008) HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity. *Mol. Pain* **4**, 48
31. Wei, H., Hämäläinen, M. M., Saarnilehto, M., Koivisto, A., and Pertovaara, A. (2009) Attenuation of mechanical hypersensitivity by an antagonist of the TRPA1 ion channel in diabetic animals. *Anesthesiology* **111**, 147–154
32. Hughes, S. R., and Brain, S. D. (1991) A calcitonin gene-related peptide (CGRP) antagonist (CGRP₈₋₃₇) inhibits microvascular responses induced by CGRP and capsaicin in skin. *Br. J. Pharmacol.* **104**, 738–742
33. Costa, S. K., De Nucci, G., Antunes, E., and Brain, S. D. (2000) Involvement of vanilloid receptors and purinoceptors in the *Phoneutria nigriventer* spider venom-induced plasma extravasation in rat skin. *Eur. J. Pharmacol.* **391**, 305–315
34. Fernandes, E. S., Passos, G. F., Campos, M. M., Araújo, J. G., Pesquero, J. L., Avellar, M. C., Teixeira, M. M., and Calixto, J. B. (2003) Mechanisms underlying the modulatory action of platelet activating factor (PAF) on the upregulation of kinin B1 receptors in the rat paw. *Br. J. Pharmacol.* **139**, 973–981
35. Terneus, M. V., Brown, J. M., Carpenter, A. B., and Valentovic, M. A. (2008) Comparison of Sadenosyl-L-methionine (SAME) and N-acetylcysteine (NAC) protective effects on hepatic damage when administered after acetaminophen overdose. *Toxicology* **244**, 25–34
36. Stefanova, T. H., Ratcheva, I., Nikolova, N. J., and Neychev, H. O. (2010) Effect of yeast superoxide dismutase treatment on some mediators of inflammation during adjuvant-induced arthritis in mice. *Z. Naturforsch. C* **65**, 141–147
37. Keeble, J. E., Bodkin, J. V., Liang, L., Wodarski, R., Davies, M., Fernandes, E. S., Coelho C. de F., Russell, F., Graepel, R., Muscara, M. N., Malcangio, M., and Brain, S. D. (2009) Hydrogen peroxide is a novel mediator of inflammatory hyperalgesia, acting via transient receptor potential vanilloid 1-dependent and independent mechanisms. *Pain* **141**, 135–142
38. Guzik, T. J., and Channon, K. M. (2005) Measurement of vascular reactive oxygen species production by chemiluminescence. *Methods Mol. Med.* **108**, 73–89
39. Ford-Hutchinson, A. W., Bray, M. A., Doig, M. V., Shipley, M. E., and Smith, M. J. (1980) Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. *Nature* **286**, 264–265
40. Demetri, G. D., and Griffin, J. D. (1991) Granulocyte colony-stimulating factor and its receptor. *Blood* **78**, 2791–2808
41. El-Benna, J., Dang, P. M., and Gougerot-Pocidalo, M. A. (2008) Priming of the neutrophil NADPH oxidase activation: role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane. *Semin. Immunopathol.* **30**, 279–289
42. Yokomizo, T., Izumi, T., Chang, K., Takuwa, Y., and Shimizu, T. (1997) A G-protein-coupled receptor for leukotriene B₄ that mediates chemotaxis. *Nature* **387**, 620–624
43. Yokomizo, T., Kato, K., Terawaki, K., Izumi, T., and Shimizu, T. (2000) A second leukotriene B₄ receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. *J. Exp. Med.* **192**, 421–432
44. Amadesi, S., Cottrell, G. S., Divino, L., Chapman, K., Grady, E. F., Bautista, F., Karanjia, R., Barajas-Lopez, C., Vanner, S., Vergnolle, N., and Bunnett, N. W. (2006) Protease-activated receptor 2 sensitizes TRPV1 by protein kinase C ϵ - and A-dependent mechanisms in rats and mice. *J. Physiol.* **575**, 555–571
45. Ryu, H. C., Kim, C., Kim, J. Y., Chung, J. H., and Kim, J. H. (2010) UVB radiation induces apoptosis in keratinocytes by activating a pathway linked to “BLT2-reactive oxygen species”. *J. Invest. Dermatol.* **130**, 1095–1106

46. Hoyer, F. F., Albrecht, L., Nickenig, G., and Müller, C. (2012) Selective inhibition of leukotriene receptor BLT-2 reduces vascular oxidative stress and improves endothelial function in ApoE^{-/-} mice. *Mol. Cell. Biochem.* **359**, 25–31
47. Choi, J. A., Kim, E. Y., Song, H., Kim, C., and Kim, J. H. (2008) Reactive oxygen species are generated through a BLT2-linked cascade in Ras-transformed cells. *Free Radic. Biol. Med.* **44**, 624–634
48. Serezani, C. H., Aronoff, D. M., Jancar, S., and Peters-Golden, M. (2005) Leukotriene B₄ mediates p47phox phosphorylation and membrane translocation in polyunsaturated fatty acid-stimulated neutrophils. *J. Leukoc. Biol.* **78**, 976–984
49. Masaki, H., Atsumi, T., and Sakurai, H. (1995) Detection of hydrogen peroxide and hydroxyl radicals in murine skin fibroblasts under UVB irradiation. *Biochem. Biophys. Res. Commun.* **206**, 474–479
50. Gaudreault, E., Thompson, C., Stankova, J., and Rola-Pleszczynski, M. (2005) Involvement of BLT1 endocytosis and Yes kinase activation in leukotriene B₄-induced neutrophil degranulation. *Immunology* **174**, 3617–3625
51. Saiwai, H., Ohkawa, Y., Yamada, H., Kumamaru, H., Harada, A., Okano, H., Yokomizo, T., Iwamoto, Y., Okada, S. (2010) The LTB₄-BLT1 axis mediates neutrophil infiltration and secondary injury in experimental spinal cord injury. *Am. J. Pathol.* **176**, 2352–2366
52. Dent, G., Rabe, K. F., and Magnussen, H. (1997) Augmentation of human neutrophil and alveolar macrophage LTB₄ production by N-acetylcysteine: role of hydrogen peroxide. *Br. J. Pharmacol.* **122**, 758–764
53. Al-Shabanah, O. A., Mansour, M. A., and Elmazar, M. M. (1999) Enhanced generation of leukotriene B₄ and superoxide radical from calcium ionophore (A23187) stimulated human neutrophils after priming with interferon- α . *Res. Commun. Mol. Pathol. Pharmacol.* **106**, 115–128
54. Vigna, S.R., Shahid, R.A., Nathan, J.D., McVey, D. C., and Liddle, R. A. Leukotriene B₄ mediates inflammation via TRPV1 in duct obstruction-induced pancreatitis in rats. *Pancreas* **40**, 708–714
55. Liu, L., and Simon, S. A. (1997) Capsazepine, a vanilloid receptor antagonist, inhibits nicotinic acetylcholine receptors in rat trigeminal ganglia. *Neurosci. Lett.* **228**, 29–32
56. Puntambekar, P., Mukherjea, D., Jajoo, S., and Ramkumar, V. (2005) Essential role of Rac1/NADPH oxidase in nerve growth factor induction of TRPV1 expression. *J. Neurochem.* **95**, 1689–1703
57. Arruda, M. A., and Barja-Fidalgo, C. (2009) NADPH oxidase activity: In the crossroad of neutrophil life and death. *Front. Biosci.* **14**, 4546–4556
58. Sheppard, F. R., Kelher, M. R., Moore, E. E., McLaughlin, N. J., Banerjee, A., and Silliman, C. C. (2005) Structural organization of the neutrophil NADPH oxidase: phosphorylation and translocation during priming and activation. *J. Leukoc. Biol.* **78**, 1025–1042
59. Rada, B., and Leto, T. L. (2008) Oxidative innate immune defenses by Nox/Duox family NADPH oxidases. *Contrib. Microbiol.* **15**, 164–187
60. Bessac, B. F., Sivula, M., von Hehn, C. A., Escalera, J., Cohn, L., and Jordt, S. E. (2008) TRPA1 is a major oxidant sensor in murine airway sensory neurons. *J. Clin. Invest.* **118**, 1899–1910
61. Gujral, J. S., Hinson, J. A., Farhood, A., and Jaeschke, H. (2004) NADPH oxidase-derived oxidant stress is critical for neutrophil cytotoxicity during endotoxemia. *Am. J. Physiol. Gastrointest. Liver Physiol.* **287**, G243–G252
62. Prokopowicz, Z., Marcinkiewicz, J., Katz, D. R., and Chain, B. M. (2012) Neutrophil myeloperoxidase: soldier and statesman. *Arch. Immunol. Ther. Exp. (Warsz.)* **60**, 43–54
63. Kato, S., Aoshima, H., Saitoh, Y., and Miwa, N. (2011) Fullerene-C60 incorporated in liposome exerts persistent hydroxyl radical-scavenging activity and cytoprotection in UVA/B-irradiated keratinocytes. *J. Nanosci. Nanotechnol.* **11**, 3814–3823

Received for publication September 24, 2012.
Accepted for publication December 10, 2012.